Status:
UNKNOWN
The Effect of Solifenacin Used for Lower Urinary Tract Symptoms on Sexual Function
Lead Sponsor:
Istanbul University
Collaborating Sponsors:
Arnavutkoy State Hospital
Conditions:
Urge Incontinence
Urgency-frequency Syndrome
Eligibility:
FEMALE
18-90 years
Brief Summary
This study aims to determine whether Solifenacine used for lower urinary tract symptoms improves sexual function and if so does this improvement differs between premenopausal and postmenopausal women.
Detailed Description
Solifenacin is an anticholinergic drug that is commonly used for lower urinary tract symptoms such as urgency, frequency and urge urinary incontinence. Solifenacin use and sexual function improvement ...
Eligibility Criteria
Inclusion
- Women presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that are planned to start treatment with Solifenacin 5 mg (Vesicare 5mg).
- Patients agreed to involve in the study, having discussed other treatment options and possible side effects of the medication.
- Informed consent obtained
Exclusion
- urinary tract infection
- stress urinary incontinence
- urinary retention
- grade 2 or above pelvic organ prolapse according to POP-Q scale
- Solifenacin contraindications such as narrow angle glaucoma, allergy of Solifenacin or other components of the drug.
Key Trial Info
Start Date :
June 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 3 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05391425
Start Date
June 3 2021
End Date
June 3 2024
Last Update
May 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Arnavutkoy State Hospital
Istanbul, Arnavutkoy, Turkey (Türkiye), 34275